Metaphors used by the pioneer in quantitative MR imaging, Prof. Dr. Paul S. Tofts, for describing the paradigm shift of MRI utility from qualitative to quantitative imaging is something as below:
In qualitative imaging era MRI is applied as a sophisticated camera whereas
in quantitative imaging era MRI serves as a sophisticated measuring device.
This analogy can be generalized to any imaging modalities that delivers accurate, reliable measurements in repetitive manner. Certainly we expect the readings from the instruments, the parameters or biomarkers in imaging sense, should be physiologically relevant. In case the parameters are not only physiologically but proven to be pathologically relevant to disease course during a treatment regimen this opens a gate for medical imaging to a new realm and play a pivotal role other than its conventional diagnostic one.
We see the potentials of quantitative imaging to deliver additional information for diagnosis, evaluate the efficacy of a treatment on evidence-basis, hence support clinical decision-makings, offer insightful data for translational research and assess treatment effect during new drug developments.
We partner with radiologists, oncologists at leading hospitals, scientists of research institutes and pharmaceutical companies and provide effective solutions to assist patient care, clinical and translational research as well as clinical trials. It is one of our strengths to set up a multi-center studies and trials through the available connections and competences.